Our

Leadership

Steven Kelly

President and Chief Executive Officer
 
Toggle

Steven Kelly joined Carisma Therapeutics in February 2018 bringing nearly thirty years of experience in Pharma/Biotech at all phases of the business across multiple therapeutic categories. Prior to joining Carisma, Mr. Kelly held a number of leadership positions in the biotechnology industry including: CEO, Pinteon Therapeutics; CEO, Theracrine; CCO, BioVex; CEO, Innovive Pharmaceuticals; as well as various commercial and manufacturing roles at Sanofi, IDEC Pharmaceuticals and Amgen.

Steve holds a BS from the University of Oregon and an MBA from Cornell University.

Debora Barton, MD

Chief Medical Officer
 
Toggle

Debora Barton joined Carisma Therapeutics in November 2019. She brings 18 years of oncology experience, both in academia as a practicing physician and in the biotechnology/pharmaceutical industry.

Most recently, she served in key senior executive positions in cellular therapy and radiopharmaceutical biotech companies including Iovance Biotherapeutics and Advance Accelerator Applications, acquired by Novartis during Debora’s tenure. In her leadership roles, Debora built Clinical Development and Drug Safety teams setting up infrastructure for the conduct of clinical studies and was instrumental in obtaining FDA Breakthrough Designation for a cell therapy product and in the approval of a radiopharmaceutical agent by both FDA and EMA.

Previously, Debora spent 10 years at Celgene and Novartis, always focusing on improving the lives of cancer patients. She holds an MD from Pontificia Universidade Catolica Sao Paulo (PUC-SP) and completed her fellowship in Oncology at Federal University of Sao Paulo (UNIFESP) in Brazil.

Daniel Cushing, PhD

Chief Technology Officer
 
Toggle

Dan is responsible for product development at Carisma Therapeutics. He has over 25 years of pharmaceutical and biotechnology industry experience, including discovery research, drug development, medical affairs, and regulatory affairs. Over his career, Dan has led the development and registration of several products and launched multiple products that still enjoy success in the market.

Previously, Dan served as Chief Scientific Officer and Senior Vice President, Research and Development of Nuron Biotech Inc. and as Chief Scientific Officer and Vice President, Drug Development, Medical and Regulatory Affairs of Prism Pharmaceuticals. Earlier in his career, Dan worked at Pfizer, Merck, and Astra Merck and AstraZeneca, where he held senior positions in medical and regulatory affairs.

Dan holds a Ph.D. in Pharmacology and is a Fellow of the American College of Clinical Pharmacology.

Michael Klichinsky, PhD

Co-Founder & Vice President, Discovery Research
 
Toggle

Mike is a co-inventor of the CAR Macrophage technology and a scientific co-founder of Carisma Therapeutics Inc. In his role as VP of Discovery Research, he oversees the research & discovery efforts of the company.

Mike developed CAR Macrophages during his doctoral thesis under the co-mentorship of Saar Gill and Carl June at the University of Pennsylvania. Michael’s scientific expertise is in the intersection of immunology, synthetic biology, cancer immunotherapy, and translational pharmacology.

Mike previously earned a Doctor of Pharmacy degree from the University of Sciences in Philadelphia, and a PhD in Pharmacology from the University of Pennsylvania.

Dora Mitchell, PhD

Vice President, Business Development
 
Toggle

Dora leads business development at Carisma Therapeutics having previously served as Vice President of Operations and built the company infrastructure from its inception to a fully operating funded entity. Prior to joining Carisma, she managed the therapeutics and diagnostics company portfolio at PCI Ventures at the University of Pennsylvania (Penn), where she also directed the UPstart Company Incubator. In that role, she led the launch, funding, incubation and growth of Penn intellectual property-based businesses including CytoVas LLC, LignaMed LLC, Quantitative Radiology Solutions LLC, and Linnaeus Therapeutics Inc. and led a clinical stage diagnostics company to a successful exit. Prior to joining PCI Ventures, Dora was a member of the Health and Life Sciences team at Battelle Ventures, LP, an early-stage life science and technology company investor.

Dora holds a PhD in Molecular Biology from Princeton University and a BA in Biology from Reed College.

Tom Wilton

Chief Business Officer
 
Toggle

Tom joined Carisma Therapeutics in September 2019. He brings over 20 years of pharmaceutical and biotechnology industry experience, including corporate strategy, business development, R&D operations and marketing. Tom most recently served as the Chief Business Officer for LogicBio Therapeutics, Inc., a genome editing company, where he was responsible for leading strategy, business development and intellectual property, and supported a successful initial public offering. Prior to LogicBio, Tom was the Chief Business Officer for The University of Pennsylvania’s Gene Therapy Program, where he completed multiple partnerships that enabled the group to grow to over 250 employees. Tom began his career at GlaxoSmithKline, where he was instrumental in establishing the Rare Disease Business Unit and served in various leadership positions in the US and Europe.

Tom holds a BS from the University of London, an MA from the University of Leeds, and an MS from Brunel University.

Board of Directors

Margarita Chavez, JD

Toggle

Margarita is Managing Director at AbbVie Ventures. Margarita has lead investments in over a dozen biotech companies in the US and Europe and is responsible for AbbVie’s investments in Morphic Therapeutics, Palleon Pharmaceuticals, eFFECTOR Therapeutics, CARISMA Therapeutics, Jnana Therapeutics and Paragen Bio. Margarita brings over 20 years of dealmaking experience, with over a decade in biotech M&A, licensing, and venture.

Most recently, Margarita was a Director with Abbott’s Global Pharmaceutical Licensing & Acquisitions. Among other deals, Margarita was involved in the in-licensing of Elagolix, the acquisition of Immuven, and the acquisition of the Lupron franchise. Before joining Abbott, Margarita practiced as a corporate and securities lawyer in Silicon Valley with the firm of Brobeck Phleger & Harrison, advising in equity financings, M&A and IPOs.

Margarita currently serves as a Board Member of the New England Venture Capital Association and the MidAmerica Healthcare Investors Network and on the Advisory Board of the Santa Clara University School of Law.

Jacob Gunterberg

Toggle

Mr. Gunterberg has been Partner of HealthCap since 2007. Prior to joining HealthCap, he gained 14 years of investment banking experience, most recently with Hjalmarsson & Gunterberg Corporate Finance. His investment banking career started with ABB Aros in 1993. In 1997, he was appointed Director and responsible for the life sciences sector within the corporate finance department of Aros Securities. In 2000, he co-founded Hjalmarsson & Gunterberg Corporate Finance.

Over his career, Mr. Gunterberg has gained extensive experience from origination and execution of transactions, predominantly within the areas of Mergers & Acquisitions, IPO’s as well as public and private capital raisings. A significant share of these transactions has involved companies in the life sciences sector.

Mr. Gunterberg received his M. Sc. in Business Administration and Economics from the University of Lund and has also studied at the University of St. Gallen.

Regina Hodits, PhD

Toggle

Regina is a Managing Partner at Wellington Partners and represents the Wellington funds on the Boards of Ayoxxa, Carisma, Endostim, GTX Medical, Themis and TRiCares. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / Boston Scientific) and an external director at GlaxoSmithKline's Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European VC industry, focusing on early-stage and growth deals
in Life Sciences. She currently serves as the Spokesperson for the Board of the German PE and Venture Capital Association (BVK).

Further stations of her career were McKinsey, Atlas Venture and Apax Partners, for which she served on several boards including Bicycle Therapeutics, F-star, Jenavalve, U3 Pharma, Nitec Pharma, Egalet and Novamed. Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry.

Steven Kelly

 | 
President & Chief Executive Officer
Toggle

Steven Kelly joined Carisma Therapeutics in February 2018 bringing nearly thirty years of experience in Pharma/Biotech at all phases of the business across multiple therapeutic categories. Prior to joining Carisma, Mr. Kelly held a number of leadership positions in the biotechnology industry including: CEO, Pinteon Therapeutics; CEO, Theracrine; CCO, BioVex; CEO, Innovive Pharmaceuticals; as well as various commercial and manufacturing roles at Sanofi, IDEC Pharmaceuticals and Amgen.

Steve holds a BS from the University of Oregon and an MBA from Cornell University.

Eran Nadav, PhD

Toggle

Dr. Eran Nadav is an investor and a biopharma veteran. He has been with the investment firm TPG from 2007-2018, serving as Partner and Managing Director at the TPG Biotech fund in San Francisco. During his tenure at TPG, he led pharma and biotech deals across various geographies and stages of development. Currently he serves as Senior Advisor of TPG Biotech.

Prior to TPG, Dr. Nadav was Business Development Director at Eisai in New Jersey, where he evaluated and negotiated licensing and acquisition deals. Previously, Dr. Nadav worked for JJDC, the venture capital subsidiary of Johnson & Johnson. Earlier, he worked for Neurim Pharmaceuticals in a product development role.

Dr. Nadav holds a Ph.D. in Biochemistry, an M.Sc. magna cum laude, a B.Sc. magna cum laude, and an MBA from Tel Aviv University.

Dr. Nadav is currently a board member at Carisma Therapeutics, Fusion Pharmaceuticals, Nutrinia, Trevi Therapeutics, and Tevel Aerobotics Technologies. He is also a member at the Investment Committee at Lagunita Biosciences, a healthcare investment company and incubator. Representing TPG, Dr. Nadav was the lead investor and Chairman of the Board of Ultragenyx Pharmaceutical (Nasdaq: RARE) and Trevi Therapeutics. His other past investments and board roles include Collegium Pharmaceutical (Nasdaq: COLL), JCR Pharmaceuticals (a Japanese biopharma company, TSE: 4552), MacroGenics (Nasdaq: MGNX), ShangPharma (a China based CRO), and Eden Springs / Mey Eden (a leading European provider of workplace drinks solutions).

Althea Stillman, PhD

Toggle

Althea is Associate Director for Life Sciences at IP Group, an intellectual property commercialization company. She is part of the team that drives the company’s efforts to identify and develop early-stage technologies in the life sciences stemming from premier research institutions in North America. Currently, Althea is the investment lead for several start-ups across IP Group’s research partner network.

Althea has experience in technologies ranging across the healthcare and biotech sectors, as well as an extensive research background in neuroscience, genetics and molecular biology. Prior to joining IP Group in 2016, Althea worked for the Penn Center for Innovation, at the University of Pennsylvania.

She holds a Ph.D. in Genetics from Yale University and a B.A. in Molecular Cell Biology from the University of California, Berkeley.

Scientific Advisory Board

Saar Gill, MD, PHD

 | 
Co-Founder and Chair
Toggle

Dr. Gill is scientific co-founder of Carisma Therapeutics Inc. and currently serves as Chairman of the Scientific Advisory Board of the company. He is Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, Attending Physician, Hematologic Malignancies at the University of Pennsylvania Health System and Member of the Abramson Cancer Center at the University of Pennsylvania.

Gill obtained his medical degree from the University of Melbourne in Australia in 1999. He underwent internal medicine training at St Vincent's Hospital in Melbourne, followed by hematology training at the Peter MacCallum Cancer Centre and at the Royal Melbourne Hospital, which he completed in 2008. In 2008 he became a post-doctoral fellow at the laboratory of Robert Negrin at Stanford University, where he studied adoptive cellular therapy with NK cells.

In 2011 Dr. Gill moved to the University of Pennsylvania where he did a Bone Marrow Transplant and Cellular Therapy fellowship under Dr. David Porter, and started working in the laboratory with Dr. Michael Kalos on chimeric antigen receptor T cells for the treatment of acute myeloid leukemia (AML). The Gill Laboratory at the Center for Cellular Immunotherapies at the University of Pennsylvania was established in 2013 with the overarching goals to produce effective and safe CAR T cells for the treatment of hematologic malignancies such as leukemia and lymphoma. Current interests in the Gill Laboratory include the development of next generation gene editing approaches for adoptive cell therapy.

Reinhard Andreesen, MD, PhD

Toggle

Dr. Andreesen is Emeritus Professor of Medicine and Emeritus Head of the Department of Hematology and Oncology as well as Director Emeritus of the Regensburg Center of Interventional Immunology at the University of Regensburg.

During his fruitful career as a physician-scientist, Dr. Andreesen’s research interests included functional and molecular characterization of mononuclear phagocyte differentiation, adoptive transfer of immunological effector cells (macrophages, dendritic cells, T-cells) and autologous and allogeneic blood stem cell transplantation. As a pioneer in clinical research on cell therapy, Dr. Andreesen conducted foundational studies on adoptive transfer of non-genetically engineered macrophages in solid tumor patients. He has received numerous awards for his service and contributions to science and is author on over 300 manuscripts in peer-reviewed journals.

Dr. Andreesen’s service to the scientific community spans several decades and includes serving as President, European Macrophage und Dendritic Cell Society (EMDS), Vice-President, University of Regensburg, Scientific Director, Bavarian Immunotherapy Network and Director of the Regensburg Center for Interventional Immunology at the University of Regensburg among others.

Dr. Andreesen studied Medicine at the University of Freiburg and completed training in general medicine, internal medicine and hematology/oncology. He completed his post-doctoral research at the Max Planck Institute for Immunobiology, Freiburg.

Lisa Coussens, PhD

Toggle

Dr. Coussens is Chairwoman of the Department of Cell, Developmental & Cancer Biology, and Associate Director for Basic Research in the Knight Cancer Institute at Oregon Health & Sciences University, and holds the Hildegard Lamfrom Endowed Chair in Basic Science.

Dr. Coussens’ research is focused on revealing roles of normal immune cells in regulating various facets of solid tumor development, identifying leukocyte activities that are co-opted by early tumors to support ongoing cancer development, and responses to cytotoxic therapies. Utilizing mouse models of skin and mammary carcinoma, mesothelioma, and pancreatic adenocarcinoma, her research identified critical immune-regulated pathways for therapeutic targeting that are being translated in the clinic in combination with chemotherapy in women with metastatic triple negative breast cancer, pancreas cancer and head & neck squamous cancers.

In recognition of her research contributions to studying underlying mechanisms of cancer development, Dr. Coussens’ has been acknowledged with multiple awards including, a V Foundation Scholar Award (2000), the AACR-Gertrude B. Elion Award (2001), the AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship (2012), the 13th Rosalind E. Franklin Award from the NCI (2015), a Doctor Honoris Causa from the University of Buenos Aires, Argentina (2018), and the AACR-Princess Takamatsu Memorial Lectureship (2018).

S. Jane Flint, PhD

Toggle

Dr. Flint is Emeritus Professor of Molecular Biology at Princeton University. She received her undergraduate and graduate training in biochemistry and molecular biology at University College, London and began her studies of human adenovirus as a postdoctoral fellow at Cold Spring Harbor Laboratory, NY, and then with Phillip Sharp at MIT. During this period, she developed the first transcription maps of the viral double-stranded DNA genome and identified the minimal set of viral genes (E1A ad E1B) expressed in adenovirus-transformed rodent cells. Dr. Flint joined the faculty of Princeton University in 1977, and had been a Professor in the Department of Molecular Biology since 1988.

As an independent investigator, Dr. Flint continued to investigate adenoviral gene expression and its regulation in productively infected human cells. Contributions from this period included the first unambiguous demonstration that export of processed mRNA from the nucleus can be regulated, and is modulated by induction of selective export of viral late mRNAs in adenovirus-infected cells, the finding that the major viral core protein remains associated with viral DNA molecules that enter the nucleus and serve, and the elucidation of a genome replication-dependent repressor titration mechanism of regulation of late gene transcription. More recently, Dr. Flint’s work was focused on the impact of human adenovirus type 5 infection on normal human cells and in particular the function of the E1B 55kDa protein, whose coding sequence is deleted from the majority of adenovirus vectors and oncolytic viruses designed for therapeutic applications in humans. Her studies of effects on host cell gene expression emphasized the large difference between the responses of such normal cell and the established line of transformed cells traditionally used as hosts. Dr. Flints studies also yielded insights into the mechanisms that block the action of the tumor suppressor p53 in infected cells and revealed a previously unrecognized function of the viral E1B 55 kDa protein, inhibition of transcription of interferon-sensitive genes, that helps circumvent the interferon anti-viral defense.

In addition to peer-reviewed publications, Dr. Flint has published many invited reviews and chapters books. She is the organizing and lead author of the now classis virology text “Principles of Virology (ASM Press), now entering its 5th edition and co-author with Glen Nemerow of the specialized volume “Human Adenoviruses from Villains to Vectors”. Dr. Flint has served on various editorial boards, review panels, NIH study sections, including a term of chair of biochemistry, and the Recombinant DNA Advisory Committee. She was elected to the American Academy of Microbiology in 2000.

Carl June, MD

Toggle

Carl June, MD, is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine. He is currently director of the Center for Cellular Immunotherapies and director of Translational Research in the Abramson Cancer Center of the University of Pennsylvania, and is an investigator of the Abramson Family Cancer Research Institute. He is a graduate of the Naval Academy in Annapolis and Baylor College of Medicine in Houston, 1979. He had graduate training in immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland in 1978 and 1979, and post-doctoral training in transplantation biology with E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983 to 1986. He is board certified in Internal Medicine and Medical Oncology.

He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. In 2011, his research team published findings, which represented the first successful and sustained demonstration of the use of gene transfer therapy to treat cancer. Clinical trials utilizing this approach, in which patients are treated with genetically engineered versions of their own T-cells, are now underway for adults with chronic lymphocytic leukemia and adults and children with acute lymphoblastic leukemia. Early results in that group show that 90 percent of patients respond to the therapy, and more recently, trials of this approach have begun for patients with other blood cancers and solid tumors including pancreatic cancer, mesothelioma and the brain cancer glioblastoma. In 2014, it became the first personalized cellular therapy for the treatment of cancer therapy to receive the U.S. Food and Drug Administration’s prestigious Breakthrough Therapy designation.

He has published more than 350 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine in 2012, the William B. Coley award, the Richard V. Smalley Memorial Award from the Society for Immunotherapy of Cancer, the AACR-CRI Lloyd J. Old Award in Cancer Immunology, the Hamdan Award for Medical Research Excellence and the Paul Ehrlich and Ludwig Darmstaedter Prize. In 2014, he was elected to the American Academy of Arts and Sciences.

Hyam Levitsky, MD

Toggle

Hyam (“Hy”) Levitsky was most recently Executive Vice President and Chief Scientific Officer of Juno Therapeutics. Prior to joining Juno, Dr. Levitsky held the position of Head of Cancer Immunology Experimental Medicine at Roche Pharma Research and Development in Basel, Switzerland. Prior to that, Levitsky served as a Professor of Oncology, Medicine and Urology at The Johns Hopkins University School of Medicine, and was also an active staff member in Oncology and Medicine at The Johns Hopkins Hospital.

Dr. Levitsky received a B.S. from the University of Pennsylvania School of Engineering and Applied Science and an M.D. from The Johns Hopkins School of Medicine. He trained in Medical Oncology as a Senior Clinical Fellow at Johns Hopkins Oncology Center, rising to full Professor in 2001, and taught in the School of Medicine until 2011. His areas of expertise include Oncology, Immunology, Hematologic Malignances / Bone Marrow Transplantation (serving as Scientific Director of the George Santos Bone Marrow Transplant Program), Cellular and Molecular Medicine, and Pathobiology.

Dr. Levitsky is also a founding Executive Committee member of the Cancer Immunotherapy Consortium of the Cancer Research Institute. He was a Stohlman Scholar of the Leukemia and Lymphoma Society of America (LLS) and a member of the American Society for Clinical Investigation (ASCI). He was a founding member of MIATA (Minimal Information About T cell Assays), advises the FDA on cancer immunotherapy issues and serves on the External Scientific Advisory Board of the Pasteur Institute’s Center for Human Immunology, has consulted on a number of industry scientific advisory boards and contributes and provides editorial support to several prestigious cancer, immunology, scientific and medical publications. Dr. Levitsky holds several patents.